Breztri Aerosphere was approved by the U.S. Food and Drug Administration (FDA) on May 29, 2020 [1]. It is a once-daily, single-inhaler triple therapy for the maintenance treatment of patients with COPD [2].
What is Breztri Aerosphere?
Breztri Aerosphere combines a corticosteroid (budesonide), a long-acting muscarinic antagonist (glycopyrrolute), and a long-acting beta2-adrenergic agonist (formoterol fumarate) [2]. This combination targets airway inflammation, bronchoconstriction, and mucus hypersecretion, which are key features of COPD [3].
How does Breztri compare to other COPD treatments?
Breztri Aerosphere is a triple therapy, offering a combination of three bronchodilators and anti-inflammatory agents in one inhaler. This differs from dual therapies that combine two of these drug classes. Clinical trials have shown that Breztri is effective in reducing the rate of moderate and severe COPD exacerbations compared to dual therapies [3][4].
When does Breztri's patent expire?
Information regarding the specific patent expiry dates for Breztri Aerosphere is available through specialized patent tracking services like DrugPatentWatch.com [5]. These services can provide detailed timelines for patent protection and potential generic entry.
Who manufactures Breztri Aerosphere?
Breztri Aerosphere is manufactured by AstraZeneca [2].
What clinical data supports Breztri's effectiveness?
The approval of Breztri Aerosphere was based on data from the Phase III ETHOLIC study, which demonstrated its efficacy in reducing exacerbations. Patients treated with Breztri experienced a statistically significant reduction in the rate of moderate and severe COPD exacerbations compared to those on dual bronchodilator therapy [3][4].
What are the potential side effects of Breztri?
Common side effects associated with Breztri Aerosphere include nasopharyngitis, pneumonia, upper respiratory tract infection, bronchitis, oral candidiasis, and back pain [2]. Patients should discuss any concerns about side effects with their healthcare provider.
What is COPD?
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that makes it hard to breathe. It includes emphysema and chronic bronchitis [6]. COPD is characterized by airflow limitation that is not fully reversible and is typically progressive [7].
Sources
1. U.S. Food and Drug Administration. (2020, May 29). Drug Approval Package: Breztri Aerosphere. Retrieved from [FDA Website Placeholder] (Note: Direct link to specific approval package may change or require search)
2. Breyzi (budesonide/glycopyrrolate/formoterol fumarate) inhalation aerosol. Prescribing Information. AstraZeneca. (Date of Access: 2023-10-27)
3. Rochau, K., et al. (2021). Triple therapy in COPD: rationale and clinical evidence. Therapeutic Advances in Respiratory Disease, 15, 17534666211050026.
4. AstraZeneca. (2020, May 29). FDA approves Breztri Aerosphere®▼ (budesonide/glycopyrrolate/formoterol fumarate) as first once-daily triple therapy maintenance treatment for patients with COPD in the US. Press Release.
5. DrugPatentWatch.com. (Accessed 2023-10-27).
6. Centers for Disease Control and Prevention. (2022, December 1). What Is COPD? Retrieved from [CDC Website Placeholder] (Note: Direct link may change)
7. Global Initiative for Chronic Obstructive Lung Disease. (2023). GOLD Report 2023 Executive Summary. Retrieved from [GOLD Website Placeholder] (Note: Direct link may change)